Synthesis of polymeric thiazolidinedione and fibrate conjugates

Archives of Pharmacal Research

Volumn 31, Issue 2, 2008, Pages 148-153

  Kim, YoonJung ^a   Kang, Bomi ^a   Jeon, Raok ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Clofibrate; Pioglitazone; Polymer; PPAR; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CLOFIBRIC ACID; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; METHACRYLIC ACID; METHACRYLIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; POLYMER; SOLVENT;

ARTICLE; CHEMISTRY; DRUG POTENTIATION; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

CLOFIBRIC ACID; HYPOGLYCEMIC AGENTS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; METHACRYLATES; MOLECULAR WEIGHT; POLYMERS; PPAR ALPHA; PPAR GAMMA; SOLVENTS; THIAZOLIDINEDIONES;

EID: 42949110308     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1133-2     Document Type: Article

References (15)

1. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebocontrolled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23, 1605-1611 (2000).
2. Barnett, D., Craig, J. G., Robinson, D. S., and Rogers, M. P., Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br. J. Clin. Pharmacol., 4, 455-458 (1977).
3. Berger, J. and Moller, D. E., The mechanisms of action of PPARs. Annu. Rev. Med., 53, 409-435 (2002).
4. Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Smith, S. A., and Thurlby, P. L., [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994).
5. Cox, S. L., Tesaglitazar: a promising approach in type 2 diabetes. Drugs Today (Barc), 42, 139-146 (2006).
6. Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 20, 649-688 (1999).
7. Devasthale, P. V., Chen, S., Jeon, Y., Qu, F., Shao, C., Wang, W., Zhang, H., Cap, M., Farrelly, D., Golla, R., Grover, G., Harrity, T., Ma, Z., Moore, L., Ren, J., Seethala, R., Cheng, L., Sleph, P., Sun, W., Tieman, A., Wetterau, J. R., Doweyko, A., Chandrasena, G., Chang, S. Y., Humphreys, W. G., Sasseville, V. G., Biller, S. A., Ryono, D. E., Selan, F., Hariharan, N., and Cheng, P. T., Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2- phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem., 48, 2248-2250 (2005).
8. Ibrahimi, A., Teboul, L., Gaillard, D., Amri, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimaldi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol., 46, 1070-1076 (1994).
9. Kersten, J. R., Toller, W. G., Gross, E. R., Pagel, P. S., and Warltier, D. C., Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am. J. Physiol. Heart Circ. Physiol., 278, H1218-H1224 (2000).
10. Kletzien, R. F., Clarke, S. D., and Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol., 41, 393-398 (1992).
11. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995).
12. Ljung, B., Bamberg, K., Dahllof, B., Kjellstedt, A., Oakes, N. D., Ostling, J., Svensson, L., and Camejo, G., AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res., 43, 1855-1863 (2002).
13. Sohda, T., Momose, Y., Meguro, K., Kawamatsu, Y., Sugiyama, Y., and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung, 40, 37-42 (1990).
14. Yajima, K., Hirose, H., Fujita, H., Seto, Y., Fujita, H., Ukeda, K., Miyashita, K., Kawai, T., Yamamoto, Y., Ogawa, T., Yamada, T., and Saruta, T., Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am. J. Physiol. Endocrinol. Metab., 284, E966-E971 (2003).
15. Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., and Horikoshi, H., Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem., 32, 421-428 (1989).